Document is current
Any future updates will be listed below
-
Authors
Szabó, Máté https://orcid.org/0009-0002-0936-4911
Hujber, Zoltán
Harsányi, Judit
Szatmári, Balázs
Dombi, Zsófia B.
Magyar, Gabriella
Hegedűs, Zsuzsanna
Ratskó, Piroska
Pásztor Mészáros, Gabriella
Barabássy, Ágota
-
Funding
Funding for this research was provided by:
Gedeon Richter
- License Information
-
More Information
Article History
Accepted: 16 September 2024
First Online: 20 October 2024
Declarations
:
: Study was financed by Gedeon Richter Plc.
: The authors are employees of Gedeon Richter Plc., the originator of cariprazine.
: The study data are owned by Gedeon Richter Plc (Budapest, Hungary). Parts of data can be made available upon request.
: The study was conducted only in Bulgaria. Bulgarian Central Ethics Committee approved the Clinical Trial Application on 17 April 2019. The Ministry of Health granted approval on 23 March 2020 (with this approval ’full approval’ was obtained for study conduct).
: ICH-E6 GCP guidelines were followed and written informed consent was obtained from all participants.
: Not applicable.
: Not applicable.
: All authors participated in the writing, editing, and critical revision for intellectual content, and approved the final version of this manuscript. Specific roles: Máté Szabó (Clinical Project Manager and Supervisor Medical Monitor), Zoltán Hujber (Clinical Project Manager), Judit Harsányi (study design), Balázs Szatmári (data interpretation), Gabriella Pásztor Mészáros (Principal Analyst), Zsuzsanna Hegedűs and Piroska Ratskó (bioanalytical measurements), Gabriella Magyar (pharmacokinetics and associated statistical analysis), Zsófia B. Dombi (writing assistance), Ágota Barabássy (data interpretation, study design and writing assistance).
